An mGluR2 potentiator and cysteinyl leukotriene 1 antagonist, LY2300559, has proof of concept evidence for efficacy as migraine prevention in a randomized double-blind placebo-controlled trial (abstract only published) [159]. This evidence concerns the gene GRM2 and migraine disorder.